Document:

Exhibit 10.2

 

Attorney Docket No. 520-00101.PRV4

 

Assignment
of Provisional Patent Application

 

WHEREAS, Richard James Douglas Rouse,
4182 Pamela Court, San Diego, CA 92117 (hereinafter “ASSIGNOR”), has made an invention entitled:

 

“A METHOD
FOR THERAPEUTIC DEVELOPMENT, PREPARATION AND 

ADMINISTRATION”

 

described in United States Provisional
Patent Application Serial No. 61/927,992, filed January 16, 2014 (hereinafter the “Invention”), and

 

WHEREAS, CDx, Inc. (hereinafter
“ASSIGNEE”), a corporation of the state of Delaware, having a place of business at 4225 Executive Square Suite 600,
La Jolla, CA 92037, desires to acquire all of the ASSIGNOR’S interest in the Invention;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer unto ASSIGNEE, its
successors, assigns and legal representatives, the full and exclusive right, title and interest, in the United States and all foreign
countries, to the Invention, in the aforesaid application, and to all subsequent applications based thereon, or claiming priority
thereto, including any and all utility applications, continuations, divisions, reissues and substitutes of such subsequent applications,
together with the right of priority under the International Convention for the Protection of Industrial Property, Inter-American
Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States
of America adheres.

 

AND ASSIGNOR hereby agrees to execute any
papers requested by ASSIGNEE, its successors, assigns and legal representatives, deemed essential to ASSIGNEE’S full protection
and title in and to each invention hereby transferred.

 

ASSIGNOR furthermore agrees upon request
of said ASSIGNEE, and without further remuneration, to execute any and all papers desired by said ASSIGNEE for the filing and granting
of the aforesaid subsequent U.S. and of foreign applications and the perfecting of title thereto in said ASSIGNEE.

 

    	1 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV4

 

ASSIGNOR hereby warrants and
covenants that ASSIGNOR has the full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and
will not execute any instrument or assignment in conflict herewith.

 

	Signature of Inventor:	/s/ Richard  James Douglas
    Rouse
	Inventor’s Name:	Richard  James Douglas Rouse
	 	 
	 	 
	Date:	7-2-14

 

    	2 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV3

 

Assignment
of Provisional Patent Application

 

WHEREAS, Richard James Douglas
Rouse, 4182 Pamela Court, San Diego, CA 92117 (hereinafter “ASSIGNOR”), has made an invention entitled:

 

“A
PORTABLE GAS CHROMATOGRAPHIC ANALYSIS AND DISTRIBUTION SYSTEM FOR THE EXTRACTION AND DELIVERY OF COMPOUNDS IN CANNABIS”

 

described in United States Provisional
Patent Application Serial No. 61/864,517, filed August 9, 2013 (hereinafter the “Invention”), and

 

WHEREAS, CDx, Inc. (hereinafter
“ASSIGNEE”), a corporation of the state of Delaware, having a place of business at 4225 Executive Square Suite 600,
La Jolla, CA 92037, desires to acquire all of the ASSIGNOR’S interest in the Invention;

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer
unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest, in the United
States and all foreign countries, to the Invention, in the aforesaid application, and to all subsequent applications based thereon,
or claiming priority thereto, including any and all utility applications, continuations, divisions, reissues and substitutes of
such subsequent applications, together with the right of priority under the International Convention for the Protection of Industrial
Property, Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements
to which the United States of America adheres.

 

AND ASSIGNOR hereby agrees to
execute any papers requested by ASSIGNEE, its successors, assigns and legal representatives, deemed essential to ASSIGNEE’S full
protection and title in and to each invention hereby transferred.

 

ASSIGNOR furthermore agrees upon
request of said ASSIGNEE, and without further remuneration, to execute any and all papers desired by said ASSIGNEE for the filing
and granting of the aforesaid subsequent U.S. and of foreign applications and the perfecting of title thereto in said ASSIGNEE.

 

    	1 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV3

 

ASSIGNOR hereby warrants and
covenants that ASSIGNOR has the full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and
will not execute any instrument or assignment in conflict herewith.

 

	Signature of Inventor:	/s/ Richard James Douglas Rouse
	Inventor’s Name:	Richard James Douglas Rouse
	 	 
	Date:	7-2-14

 

    	2 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV2

  

Assignment
of Provisional Patent Application

 

WHEREAS, Richard James Douglas Rouse,
4182 Pamela Court, San Diego, CA 92117 (hereinafter “ASSIGNOR”), has made an invention entitled:

 

“A PORTABLE
GAS CHROMATOGRAPHIC ANALYSIS AND DISTRIBUTION

SYSTEM FOR THE EXTRACTION AND DELIVERY OF COMPOUNDS”

 

described in United States Provisional
Patent Application Serial No. 61/864,515, filed August 9, 2013 (hereinafter the “Invention”), and

 

WHEREAS, CDx, Inc. (hereinafter
“ASSIGNEE”), a corporation of the state of Delaware, having a place of business at 4225 Executive Square Suite 600,
La Jolla, CA 92037, desires to acquire all of the ASSIGNOR’S interest in the Invention;

 

NOW, THEREFORE, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer unto ASSIGNEE, its
successors, assigns and legal representatives, the full and exclusive right, title and interest, in the United States and all foreign
countries, to the Invention, in the aforesaid application, and to all subsequent applications based thereon, or claiming priority
thereto, including any and all utility applications, continuations, divisions, reissues and substitutes of such subsequent applications,
together with the right of priority under the International Convention for the Protection of Industrial Property, Inter-American
Convention Relating to Patents, Designs and Industrial Models, and any other international agreements to which the United States
of America adheres.

 

AND ASSIGNOR hereby agrees to execute any
papers requested by ASSIGNEE, its successors, assigns and legal representatives, deemed essential to ASSIGNEE’S full protection
and title in and to each invention hereby transferred.

 

ASSIGNOR furthermore agrees upon request
of said ASSIGNEE, and without further remuneration, to execute any and all papers desired by said ASSIGNEE for the filing and granting
of the aforesaid subsequent U.S. and of foreign applications and the perfecting of title thereto in said ASSIGNEE.

 

    	1 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV2

 

ASSIGNOR hereby warrants and covenants
that ASSIGNOR has the full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not
execute any instrument or assignment in conflict herewith.

 

	Signature of Inventor: 	 	/s/ RicharJames Douglas Rouse
	Inventor’s Name:	 	RicharJames Douglas Rouse
	 	 	 
	Date:	 	7-2-14

 

    	2 of 2

    	 

    

  

Attorney Docket No. 520-00101.PRV1

 

Assignment
of Provisional Patent Application

  

WHEREAS, Richard James Douglas
Rouse, 4182 Pamela Court, San Diego, CA 92117 (hereinafter “ASSIGNOR”), has made an invention entitled:

 

“A PORTABLE
CHEMICAL ANALYSIS METHOD BY VOLATILIZATION AND

SUBLIMATION”

 

described in United States Provisional
Patent Application Serial No. 61/846,996, filed July 16, 2013 (hereinafter the “Invention”), and

 

WHEREAS, CDx, Inc. (hereinafter
“ASSIGNEE”), a corporation of the state of Delaware, having a place of business at 4225 Executive Square Suite 600,
La Jolla, CA 92037, desires to acquire all of the ASSIGNOR’S interest in the Invention;

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR does hereby sell, assign and transfer
unto ASSIGNEE, its successors, assigns and legal representatives, the full and exclusive right, title and interest, in the United
States and all foreign countries, to the Invention, in the aforesaid application, and to all subsequent applications based thereon,
or claiming priority thereto, including any and all utility applications, continuations, divisions, reissues and substitutes of
such subsequent applications, together with the right of priority under the International Convention for the Protection of Industrial
Property, Inter-American Convention Relating to Patents, Designs and Industrial Models, and any other international agreements
to which the United States of America adheres.

 

AND ASSIGNOR hereby agrees to
execute any papers requested by ASSIGNEE, its successors, assigns and legal representatives, deemed essential to ASSIGNEE’S full
protection and title in and to each invention hereby transferred.

 

ASSIGNOR furthermore agrees upon
request of said ASSIGNEE, and without further remuneration, to execute any and all papers desired by said ASSIGNEE for the filing
and granting of the aforesaid subsequent U.S. and of foreign applications and the perfecting of title thereto in said ASSIGNEE.

 

    	1 of 2

    	 

    

 

Attorney Docket No. 520-00101.PRV2

 

ASSIGNOR hereby warrants and covenants
that ASSIGNOR has the full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not
execute any instrument or assignment in conflict herewith.

 

	Signature of Inventor:	/s/ Richard James Douglas Rouse
	Inventor’s Name:	Richard James Douglas Rouse
	 	 
	Date:	7-2-14

 

    	2 of 2Exhibit 10.3

 

EMPLOYMENT AGREEMENT

 

This
EMPLOYMENT AGREEMENT is entered into as of October 15, 2014 by and between CDx, Inc., a Delaware Company (the “Company”),
and Daniel Yazbeck (“Executive”), and is effective upon approval
of a majority vote of The Board of Directors.

 

1. DUTIES AND RESPONSIBILITIES.

 

A.  Executive shall serve
as the Company’s Chief Executive Officer or such other title or position as may be designated from time to time by the Board
of Directors. Executive shall report to and perform the duties and responsibilities assigned to him by the Company’s Board
of Directors.

 

B.  Executive agrees to devote
his full time and attention to the Company, to use his best efforts to advance the business and welfare of the Company, to render
his services under this Agreement fully, faithfully, diligently, competently and to the best of his ability, and not to engage
in any other employment activities.

 

C.  Executive shall be based
at the Company’s office located in La Jolla, California, but Executive may be required to travel to other geographic locations
in connection with the performance of his Executive duties.

 

2. PERIOD OF EMPLOYMENT.

 

A.  Executive’s
employment with the Company shall be governed by the provisions of this Agreement for the period commencing September 1, 2014 and
continuing until this Agreement terminates pursuant to written notification by either the Company or Executive, which notification
may occur at any time for any reason. The period during which the Executive provides services to the Company pursuant to this Agreement
shall be referenced in this Agreement as the “Employment Period.”

 

B.  During the first five
(5) years of this Agreement, if Executive is terminated other than for Cause (as defined below) or if he resigns for Good Reason
(as defined below), he shall be entitled to the payments and other benefits, set forth in Paragraph 7 of this Agreement.

 

3. CASH COMPENSATION.

 

A.  Executive’s
initial base salary (the “Base Salary”) shall be One Hundred Eighty
Thousand Dollars ($180,000) per year payable in accordance with the Company’s standard payroll schedule. Executive’s
compensation shall be subject to periodic review by the Company, and may be increased in the Company’s discretion.

 

    	 

    	 

    

  

B.  For
each fiscal year during the Employment Period, Executive shall be eligible for an incentive bonus. For each full fiscal year of
employment, Executive shall be eligible for an incentive bonus of up to one hundred percent (100%) of his annual base salary and
his performance objectives shall be set such that one hundred percent (100%) completion of his objectives shall entitle him to
at least seventy-five percent (75%) of the bonus (the “Target Bonus”). During the first year of employment
the Executive shall be eligible for the bonus plan below. After year 1, the bonus amount will be based on the following factors:
(1) the financial performance of the Company as determined and measured by the Company’s Board of Directors, and (2) Executive’s
achievement of management targets and goals as set by the Company. The bonus amount is intended to reward contribution to the Company’s
performance over an entire fiscal year, and on the basis of continuing, cumulative contribution, and consequently will be paid
only if Executive is employed and in good standing at the time of bonus payments, which will occur each quarter.

 

First Year Bonus Plan Structure:

 

	CEO Bonus Plan	 	 	 	 	Required Timing	 
	Total Annual Bonus Comp Available	 	$	180,000	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Bonus 1	 	 	 	 	 	 	 	 
	Delivery of a handheld Working Prototype	 	$	45,000	 	 	 	Oct-14	 
	 	 	 	 	 	 	 	 	 
	Bonus 2	 	 	 	 	 	 	 	 
	Delivery of Beta Units (250-300)	 	$	45,000	 	 	 	Dec-14	 
	 	 	 	 	 	 	 	 	 
	Bonus 3	 	 	 	 	 	 	 	 
	Delivery of Q1 Production Units (2,000+)	 	$	45,000	 	 	 	Feb-Mar2015	
	 	 	 	 	 	 	 	 	 
	Bonus 4	 	 	 	 	 	 	 	 
	Delivery of Functional Organa Sensor	 	$	45,000	 	 	 	Mar-15	 

 

C. The Company shall deduct
and withhold from the compensation payable to Executive hereunder any and all applicable Federal, State and Local income and employment
withholding taxes and any other amounts required or authorized by Executive to be deducted or withheld by the Company under applicable
statutes, regulations, ordinances or orders governing or requiring the withholding or deduction of amounts otherwise payable as
compensation or wages to employees.

 

4.  EQUITY PARTICIPATION.
Separate from this Agreement and pursuant and subject to the terms and conditions of the Company’s Stock Option Plan and
Stock Option Agreement, Executive has been granted options to purchase five hundred thousand (500,000) shares of the Company’s
common stock, which options are vesting per the Company vesting schedule. Any further options will be made pursuant and subject
to the terms and conditions of the Company’s stock option plan and stock option agreement.

 

5.  EXPENSE REIMBURSEMENT.
In addition to the compensation specified in Paragraph 3, Executive shall be entitled, in accordance with the reimbursement policies
in effect from time to time, to receive reimbursement from the Company for reasonable business expenses incurred by Executive in
the performance of his duties hereunder, provided Executive furnishes the Company with vouchers, receipts and other details of
such expenses in the form required by the Company sufficient to substantiate a deduction for such business expenses under all applicable
rules and regulations of Federal and State taxing authorities.

 

    	 

    	 

    

  

6.  FRINGE BENEFITS.

 

A.  Executive shall, throughout
the Employment Period, be eligible to participate in all group term life insurance plans, group health plans, accidental death
and dismemberment plans and short-term disability programs and other Executive perquisites which are made available to the Company’s
Executives and for which Executive qualifies. Please refer to the Company’s Employee Handbook and Summary Plan Descriptions
for further information concerning these benefits. Additionally, upon submission of appropriate documentation, Executive shall
be entitled to be reimbursed for supplemental insurance products including life insurance at a cost of up to an additional Fifteen
Thousand Dollars ($15,000) per year.

 

B.  Executive shall earn vacation
time during the Employment Period at the rate of four weeks per year. Vacation shall accrue and be taken pursuant to the Company’s
vacation benefit policy set forth in the Company’s Employee Handbook.

 

C.  Company will provide a
leased vehicle with operating expenses, whose payments will not exceed $800 per month.

 

7.   SEVERANCE PAY FOR EXERCISE
OF THE AT-WILL CLAUSE. Notwithstanding any of the provisions of this Agreement, Executive’s employment with the Company is
at will, which means that it is not for a specific term and may be terminated by either the Company or Executive at any time, for
any reason without advance notice. Similarly the Company may change the terms and conditions of Executive’s employment at
any time, for any reason, without advance notice. Should the Company terminate Executive’s employment for Cause, as defined
below, or should Executive voluntarily resign other than for Good Reason, the Company shall have no obligation to Executive under
this Agreement other than for accrued but unpaid salary and vacation as of the date of termination.

 

Should the Company terminate
Executive’s employment other than for Cause during the first five years of this Agreement, or should Executive resign for
Good Reason, the Company shall have no further obligation under this Agreement, except that the Company will continue to pay Executive’s
base salary for a two year period, (less, if applicable, any long-term disability payments) and the Target Bonus for a one year
period following termination of Executive’s employment on the normal payroll dates, and in addition one hundred percent (100%)
of Executive’s then-outstanding unvested stock options shall immediately vest.

 

8.  GOOD REASON. For Purposes of this agreement, “Good
Reason” shall mean:

 

A. A material reduction in the
duties, responsibilities, status, reporting responsibilities, title, or offices that Executive had with the Company immediately
before the reduction.

 

    	 

    	 

    

  

B.  A reduction by more than
ten percent (10%) of the total annual cash compensation (defined as Base Salary and Target Bonus) that Executive was eligible to
receive from the Company and its affiliates immediately before the reduction, except a reduction that is part of, and consistent
with, an across-the-board reduction in the salaries of senior officers of the Company.

 

C.  A Change in Control (as
defined below) in which the Executive is not offered a similar portion at no less than ninety percent (90%) of Executive’s
last total compensation (defined as Base Salary plus Target Bonus of sixty percent (60%).

 

D.  The failure of any successor
to the Company by merger, consolidation or acquisition of all or substantially all of the business of the Company to assume the
Company’s obligations under this Agreement.

 

E.  A material breach by the
Company of its obligations under this Agreement.

 

9.  CAUSE.
For purposes of this Agreement, “Cause” shall mean a reasonable
belief by the Board of Directors that Executive has engaged in any one of the following: (i) financial dishonesty, including, without
limitation, misappropriation of funds or property (ii) refusal to comply with reasonable directives of the Board of Directors;
(iii) negligence or reckless or willful misconduct in the performance of Executive’s duties; (iv) failure to perform, or
continuing neglect in the performance of, duties assigned to Executive; (v) the criminal conviction of, or plea of nolo contendre
to, any felony involving moral turpitude or fraud; (vi) the material breach of any provision of this Agreement; (vii) violation
of Company policies including, without limitation, the Company’s policies on equal employment opportunity and prohibition
of unlawful harassment; (viii) death of the Executive; or (ix) a disability which continues for a period in excess of 365 days.

 

A termination as a result of a Change in Control
shall not constitute cause.

 

10.  CHANGE
IN CONTROL. For purposes of this Agreement “Change In Control” shall
mean any of the following transactions effecting a change in ownership or control of the Company:

 

(i)  a merger, consolidation
or reorganization approved by the Company’s stockholders, UNLESS securities representing more than fifty percent (50%) of
the total combined voting power of the voting securities of the successor Company are immediately thereafter beneficially owned,
directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Company’s outstanding
voting securities immediately prior to such transaction, or

 

(ii)  any stockholder-approved
transfer or other disposition of all or substantially all of the Company’s assets, or

 

(iii)  the acquisition, directly
or indirectly, by any person or related group of persons (other than the Company or a person that directly or indirectly controls,
is controlled by, or is under common control with, the Company), of beneficial ownership (within the meaning of Rule 13d-3 of the
1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting power of the Company’s outstanding
securities pursuant to a tender or exchange offer made directly to the Company’s stockholders.

 

    	 

    	 

    

  

In no event, however, shall
a Change in Control be deemed to occur in connection with any public offering of the Common Stock.

 

11.  RESTRICTIVE COVENANTS. During the Employment
Period:

 

Executive shall devote Executive’s
full time and energy solely and exclusively to the performance of Executive’s duties described herein, except during periods
of illness or vacation periods.

 

Executive, however, shall have
the right to perform such incidental services as are necessary in connection with (a) Executive’s private passive investments,
but only if Executive is not obligated or required to (and shall not in fact) devote any managerial efforts which interfere with
the services required to be performed by him, or (b) Executive’s charitable or community activities, or participation in
trade or professional organizations, but only if such incidental services do not interfere with the performance of Executive’s
services to the Company.

 

12.  NON-COMPETITION DURING
THE EMPLOYMENT PERIOD. Executive acknowledges and agrees that given the extent and nature of the confidential and proprietary information
he will obtain during the course of his employment with the Company, it would be inevitable that such confidential information
would be disclosed or utilized by the Executive should he obtain employment from, or otherwise become associated with, an entity
or person that is engaged in a business or enterprise that directly competes with the Company. Consequently, during any period
for which Executive is receiving payments from the Company, either as wages or as a severance benefit, including but not limited
to severance pay pursuant to paragraph 7, Executive shall not, without prior written consent of the Company’s Board of Directors,
directly or indirectly own, manage, operate, join, control or participate in the ownership, management, operation or control of,
or be employed by or connected in any manner with, any enterprise which is engaged in any business competitive with or similar
to that of the Company; provided, however, that such restriction shall not apply to any passive investment representing an interest
of less than two percent (2%) of an outstanding class of publicly-traded securities of any Company or other enterprise which is
not, at the time of such investment, engaged in a business competitive with the Company’s business.

 

13.  NON-SOLICITATION. During
the Employment Period and for one (1) year following termination of Executive’s employment, Executive shall not encourage
or solicit any of the Company’s employees to leave the Company’s employ for any reason or interfere in any other manner
with employment relationships at the time existing between the Company and its employees. In addition, Executive shall not solicit,
directly or indirectly, business from any client of the Company, induce any of the Company’s clients to terminate their existing
business relationship with the Company or interfere in any other manner with any existing business relationship between the Company
and any client or other third party.

 

    	 

    	 

    

  

Executive acknowledges that
monetary damages may not be sufficient to compensate the Company for any economic loss which may be incurred by reason of his breach
of the foregoing restrictive covenants. Accordingly, in the event of any such breach, the Company shall, in addition to the termination
of this Agreement and any remedies available to the Company at law, be entitled to obtain equitable relief in the form of an injunction
precluding Executive from continuing such breach.

 

14.  PROPRIETARY INFORMATION.
As a condition precedent to Executive’s employment with the Company, Executive will execute the Company’s standard
At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement attached hereto as Exhibit A.
Executive’s obligations pursuant to the Confidential Information and Assignment of Inventions Agreement will survive termination
of Executive’s employment with the Company.

 

15.  SUCCESSORS AND ASSIGNS.
This Agreement is personal in its nature and the Executive shall not assign or transfer his rights under this Agreement. The provisions
of this Agreement shall inure to the benefit of, and be binding on each successor of the Company whether by merger, consolidation,
transfer of all or substantially all assets, or otherwise and the heirs and legal representatives of Executive.

 

16.  NOTICES. Any notices,
demands or other communications required or desired to be given by any party shall be in writing and shall be validly given to
another party if served either personally or if deposited in the United States mail, certified or registered, postage prepaid,
return receipt requested. If such notice, demand or other communication shall be served personally, service shall be conclusively
deemed made at the time of such personal service. If such notice, demand or other communication is given by mail, such notice shall
be conclusively deemed given forty-eight (48) hours after the deposit thereof in the United States mail addressed to the party
to whom such notice, demand or other communication is to be given as hereinafter set forth: To the Company: Human Resources Department
CDx, Inc. 4225 Executive Square Suite 600 La Jolla, CA 92036 To Executive: Daniel Yazbeck - Current address as noted in personnel
file at Company. Any party may change its address for the purpose of receiving notices, demands and other communications by providing
written notice to the other party in the manner described in this paragraph.

 

17.  GOVERNING DOCUMENTS.
This Agreement along with the documents expressly referenced in this Agreement constitute the entire agreement and understanding
of the Company and Executive with respect to the terms and conditions of Executive’s employment with the Company and the
payment of severance benefits and supersedes all prior and contemporaneous written or verbal agreements and understandings between
Executive and the Company relating to such subject matter. This Agreement may only be amended by written instrument signed by Executive
and an authorized officer of the Company. Any and all prior agreements, understandings or representations relating to the Executive’s
employment with the Company are terminated and cancelled in their entirety and are of no further force or effect.

 

    	 

    	 

    

  

18.  GOVERNING LAW. The provisions
of this Agreement will be construed and interpreted under the laws of the State of California. If any provision of this Agreement
as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction to be void or unenforceable
for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application
of such provision under circumstances different from those adjudicated by the court, the application of any other provision of
this Agreement, or the enforceability or invalidity of this Agreement as a whole. Should any provision of this Agreement become
or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage,
then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable
or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be
stricken and the remainder of this Agreement shall continue in full force and effect.

 

19.  REMEDIES. All rights
and remedies provided pursuant to this Agreement or by law shall be cumulative, and no such right or remedy shall be exclusive
of any other. A party may pursue any one or more rights or remedies hereunder or may seek damages or specific performance in the
event of another party’s breach hereunder or may pursue any other remedy by law or equity, whether or not stated in this
Agreement.

 

20.  ARBITRATION. Executive
and the Company shall separately execute an Arbitration Agreement which, among other things shall provide for arbitration of all
claims which arise out of Executive’s employment under the terms of this Agreement. This Arbitration Agreement will survive
the termination of Executive’s employment with the company.

 

21.  NO WAIVER. The waiver
by either party of a breach of any provision of this Agreement shall not operate as or be construed as a waiver of any later breach
of that provision.

 

22.  COUNTERPARTS. This Agreement
may be executed in more than one counterpart, each of which shall be deemed an original, but all of which together shall constitute
but one and the same instrument.

 

	CDx, Inc.	 
	/s/ Stephen Katz 	 
	10/20/2014	 
	By: Stephen Katz 	 
	 	 
	Title: Director	 
	 	 
	/s/ Daniel Yazbeck	 
	10/20/2014	 
	Daniel Yazbeck 	 
	 	 
	Title: CEO	 

 

    	 

    	 

    

  

EXHIBIT A

 

At-Will Employment, Confidential Information,
Invention Assignment, and Arbitration Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]